FLIBANSERIN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H21F3N4O
Molecular Weight	390.4021
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of FLIBANSERIN

Structure Search

SMILES

FC(F)(F)C1=CC(=CC=C1)N2CCN(CCN3C(=O)NC4=C3C=CC=C4)CC2

InChI

InChIKey=PPRRDFIXUUSXRA-UHFFFAOYSA-N

InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)

HIDE SMILES / InChI

Molecular Formula	C20H21F3N4O
Molecular Weight	390.4021
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:39:13 UTC 2023` Edited by `admin` on `Fri Dec 15 15:39:13 UTC 2023`
Record UNII	37JK4STR6Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FLIBANSERIN

Official Name

English

1,3-DIHYDRO-1-(2-(4-(3-(TRIFLUOROMETHYL)PHENYL)-1-PIPERAZINYL)ETHYL)-2H-BENZIMIDAZOL-2-ONE

Systematic Name

English

BIMT 17 BS

Code

English

1-(2-(4-(.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-M-TOLYL)-1-PIPERAZINYL)ETHYL)-2-BENZIMIDAZOLINONE

Systematic Name

English

BIMT-17-BS

Code

English

BIMT 17

Code

English

ADDYI

Brand Name

English

flibanserin [INN]

Common Name

English

FLIBANSERIN [MART.]

Common Name

English

Flibanserin [WHO-DD]

Common Name

English

FLIBANSERIN [USAN]

Common Name

English

BIMT-17

Code

English

FLIBANSERIN [ORANGE BOOK]

Common Name

English

ECTRIS

Brand Name

English

FLIBANSERIN [MI]

Common Name

English

Classification Tree Code System Code

WHO-ATC

G02CX02

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

NCI_THESAURUS

C66885

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

Code System Code Type Description

CHEBI

90865

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

MERCK INDEX

m5402

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

Merck Index

NCI_THESAURUS

C80769

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

IUPHAR

8182

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

ChEMBL

CHEMBL231068

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

RXCUI

1665509

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

RxNorm

DRUG CENTRAL

5022

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

FDA UNII

37JK4STR6Z

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

USAN

KK-10

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

CAS

167933-07-5

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

DAILYMED

37JK4STR6Z

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

MESH

C098107

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

DRUG BANK

DB04908

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

NDF-RT

N0000185503

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

P-Glycoprotein Inhibitors [MoA]

SMS_ID

100000081014

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

PUBCHEM

6918248

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

INN

7512

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

WIKIPEDIA

FLIBANSERIN

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

EPA CompTox

DTXSID30168445

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

EVMPD

SUB07644MIG

Created by admin on Fri Dec 15 15:39:13 UTC 2023 , Edited by admin on Fri Dec 15 15:39:13 UTC 2023

PRIMARY

Related Record Type Details


					8E4LAA4357

CYTOCHROME P450 2D6

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MINOR


					L0423Z5LDW

CYTOCHROME P450 2C8

METABOLIC ENZYME -> SUBSTRATE


					VK4SQL11C0

CYTOCHROME P450 1A2

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MINOR


					0UY97CSG1T

CYTOCHROME P450 2B6

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MINOR


					96XTC36K1B

FLIBANSERIN HYDROCHLORIDE

SALT/SOLVATE -> PARENT

Amount:


					L9DP834D1P

CYTOCHROME P450 2C9

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MINOR


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					NQI5D806LC

5-HYDROXYTRYPTAMINE RECEPTOR 2A

TARGET -> INHIBITOR

Amount:


					UKK18ES9TF

5-HYDROXYTRYPTAMINE RECEPTOR 1A

TARGET -> AGONIST

Qualification:

Ki

Amount:

Related Record Type Details


					25R3ONU51C

1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE

METABOLITE -> PARENT

Interaction Type:

MAJOR

Qualification:

URINE


					CT85K7JJ6H

2-OXO-3-(2-(4-(4-SULFO-3-(TRIFLUOROMETHYL)PHENYL)PIPERAZIN-1-YL)ETHYL)-1H-BENZIMIDAZOLE-5-SULFONIC ACID

METABOLITE -> PARENT

Interaction Type:

MAJOR


					JF6GEV6PMA

(2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(4-PIPERAZIN-1-YL-2-(TRIFLUOROMETHYL)PHENOXY)TETRAHYDROPYRAN-2-CARBOXYLIC ACID

METABOLITE -> PARENT

Interaction Type:

MAJOR


					85N6L9F9K8

(4-PIPERAZIN-1-YL-2-(TRIFLUOROMETHYL)PHENYL) HYDROGEN SULFATE

METABOLITE -> PARENT

Interaction Type:

MAJOR

Qualification:

URINE


					LC6T8F3LPW

1,3-DIHYDRO-6-(SULFOOXY)-1-(2-(4-(3-(TRIFLUOROMETHYL)PHENYL)-1-PIPERAZINYL)ETHYL)-2H-BENZIMIDAZOL-2-ONE

METABOLITE -> PARENT

Interaction Type:

MAJOR


					ZC7SGC7P97

(2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(4-(4-(2-(2-OXO-3H-BENZIMIDAZOL-1-YL)ETHYL)PIPERAZIN-1-YL)-2-(TRIFLUOROMETHYL)PHENOXY)TETRAHYDROPYRAN-2-CARBOXYLIC ACID

METABOLITE -> PARENT

Interaction Type:

MAJOR

Related Record Type Details


					37JK4STR6Z

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Tmax	PHARMACOKINETIC				SINGLE DOSE ORAL ADMINISTRATION

ORAL BIOAVAILABILITY	PHARMACOKINETIC				SINGLE DOSE ORAL ADMINISTRATION

Biological Half-life	PHARMACOKINETIC				SINGLE DOSE ORAL ADMINISTRATION